Abstract 49P
Background
There is scant data on outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy in real-world, resource-constrained settings. Factors affecting outcomes in patients who achieve pathological complete response (pCR) are insufficiently explored.
Methods
This was a retrospective analysis of HER2-positive breast cancer patients treated with neoadjuvant chemotherapy (NACT) with or without HER2-targeted therapy between Jan 2014 & Dec 2018. The endpoints were pCR, event-free survival (EFS) and overall survival (OS).
Results
1004 patients were included in the analysis with a median age of 47 years, 533 (53.1%) with cT3/T4, 466 (46.4%) with cN2/3, 527 (52.5%) with ER/PR-positive tumours, 528 (52.3%) received HER2-therapy with NACT, and 711 (70.8%) received it anytime during curative treatment. The 5-year EFS in all patients was 63.5% (95%CI 60.36-66.63%) and was significantly higher with pCR vs without pCR (86.1% vs 57.0%, HR 0.282, 95%CI 0.198-0.401, p=0.000), cT1/T2 vs cT3/T4 (66.8% vs 60.6%, HR 0.767, 95%CI 0.626-0.939, p=0.01), cN0/N1 vs cN2/N3 (67.9% vs 58.5%, HR 0.772, 95%CI 0.632-0.944, p=0.01), and ever-received vs never-received HER2-therapy (69.5% vs 50.1%, HR 0.537, 95%CI 0.438-0.659, p=0.000). The 5-year OS in all patients was 69.6% (95%CI 66.66-72.54%) and was significantly higher in pCR, cT1/T2, cN0/N1, and ever-received HER2-therapy subgroups. In the pCR subgroup (n=226), there was a trend towards higher 5-year EFS among patients with cT1/T2 vs cT3/T4 (90.0% vs 82.5%, HR 0.546, 95%CI 0.270-1.103, p=0.08), cN0/N1 vs cN2/N3 (89.3% vs 82.4%, HR 0.641, 95%CI 0.326-1.262, p=0.195), and ER/PR-positive) vs ER/PR-negative tumours (90.9% vs 83.0%, HR 0.609, 95%CI 0.291-1.274, p=0.183), but there was no difference between ever-received (n=204) vs never-received (n=22) HER2-therapy (86.1% vs 86.4%, HR 0.880, 95%CI 0.309-2.504, p=0.811).
Conclusions
The receipt of HER2-targeted therapy and achievement of pCR significantly impact survival of HER2-positive breast cancer patients treated with neoadjuvant therapy. In patients who achieve pCR baseline disease burden tends to influence survival but not receipt of HER2-targeted therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma
Presenter: Ni Putu Pusvita Dewi
Session: Poster Display
Resources:
Abstract
384P - Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan
Presenter: Wei-Chen Lu
Session: Poster Display
Resources:
Abstract
385P - The prognostic factors of induction chemotherapy followed by concurrent chemoradiotherapy in patients with HPV associated with oropharyngeal cancer
Presenter: Hyun Jin Bang
Session: Poster Display
Resources:
Abstract
386P - FOLR1 stabilized beta-catenin promotes laryngeal carcinoma progression through EGFR signal
Presenter: Huawei Tuo
Session: Poster Display
Resources:
Abstract
387P - A comprehensive analysis of the oral health status, tobacco use, and cancer prevalence among the tribal communities in India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
388P - Clinicopathological correlation of P53 expression in oral cancers
Presenter: Venkata Madhavi Bellala
Session: Poster Display
Resources:
Abstract
389P - Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab
Presenter: James A. Bonner
Session: Poster Display
Resources:
Abstract
390P - Epidemiological aspects of the development of oral cancer in the Republic of Uzbekistan
Presenter: Akhrorbek Yusupbekov
Session: Poster Display
Resources:
Abstract
391P - Lip cancer: Racial disparities, treatment modalities and long-term survival outcome in young and adults versus older age patients
Presenter: FathAlrahman Ibrahim
Session: Poster Display
Resources:
Abstract
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract